All In Biotech

Drug Trial Radar · NCT00300430

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects With Mixed Dyslipidemia

Last checked: Nov 20, 2026Latest source record: Jul 23, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,911 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,911

Actual

Start

Sep 2006

Primary completion

Mar 2008

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Mar 9, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.

Conditions

  • Dyslipidemia
  • Coronary Heart Disease
  • Mixed Dyslipidemia

Interventions

  • ABT-335 and rosuvastatin calciumDrug

    ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks

  • ABT-335 and atorvastatin calciumDrug

    ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks

  • ABT-335 and simvastatinDrug

    ABT-335 135 mg plus simvastatin daily, 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-blind Studies or in This Open-label StudyTime frame: Anytime after initiation of combination therapy (either in the double-blind or open-label study) to within 30 days after the last dose of combination therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Global Medical Information

    North Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.